Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Aichen Liu
Observed name:
A. Liu
Institutions:
City Of Hope National Medical Center,
Zhengzhou University,
Second Affiliated Hospital of Nanchang University
Observed institutions:
City Of Hope National Medical Center,
Nanchang University,
Zhengzhou University,
Second Affiliated Hospital of Nanchang University,
Second Hospital of Nanchang
ORCID:
0009-0000-6107-8264
Observed ORCID:
0009-0000-6107-8264
OpenAlex ID:
A5110072384
Consensus for HER2 alterations testing in non-small-cell lung cancer
2022
·
S. Ren
, J. Wang
, et al.
·
ESMO Open
·
149
PDF
VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
2021
·
S. Lu
, L. Wu
, et al.
·
Annals of Oncology
·
39
PDF
OA02.05 Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study
2022
·
Y.-L. Wu
, Q. Zhou
, et al.
·
Journal of Thoracic Oncology
·
22
PDF
Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection
2024
·
Jing Li
, Xiaobin Cao
, et al.
·
Cancer Epidemiology Biomarkers & Prevention
·
9
615MO Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations
2024
·
B.C. Cho
, S. Lu
, et al.
·
Annals of Oncology
·
9
PDF
125P Real-world treatment patterns in stage III NSCLC patients: Interim results of a prospective, multicenter, non-interventional study (MOOREA)
2023
·
L. Xing
, J. Yu
, et al.
·
Journal of Thoracic Oncology
·
9
PDF
642P Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLC
2024
·
Q. Zhou
, Y-L. Wu
, et al.
·
Annals of Oncology
·
8
PDF
658MO Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors
2023
·
Q. Zhou
, Y-L. Wu
, et al.
·
Annals of Oncology
·
8
PDF
Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer
2025
·
Xiaobin Cao
, Jing Li
, et al.
·
Frontiers in Immunology
·
6
LBA43 GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)
2021
·
Y-L. Wu
, Q. Zhou
, et al.
·
Annals of Oncology
·
6
519P Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
2023
·
Y. Cheng
, J. Wang
, et al.
·
Annals of Oncology
·
5
PDF
LBA58 Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study
2022
·
S. Lu
, L. Wu
, et al.
·
Annals of Oncology
·
5
PDF
349MO Results from a phase Ia/Ib Study of ESG401, a novel Trop2 antibody-drug conjugate, in patients with different subtypes of metastatic breast cancer
2024
·
F. Ma
, F. Qiu
, et al.
·
Annals of Oncology
·
3
PDF
344MO ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases
2024
·
F. Ma
, F. Qiu
, et al.
·
Annals of Oncology
·
3
PDF
65P Durvalumab combined with chemotherapy and radiotherapy in patients with oligometastatic non-small cell lung cancer (SABRcure)
2024
·
Q. Li
, H. Ma
, et al.
·
ESMO Open
·
3
22P Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trial
2023
·
H. Chen
, Y. Hu
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
P11.03 SHR-1316 in Combination With Fluzoparib in Relapsed Small-Cell Lung Cancer: An Open-Label, Multicenter, Two-Stage, Phase Ⅰb Trial
2021
·
Y. Fan
, Z. Huang
, et al.
·
Journal of Thoracic Oncology
·
2
147P PD-L1 expression influenced by osimertinib treatment in advanced EGFR T790M-positive non-small cell lung cancer patients
2021
·
Y. Yu
, L. Xia
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
388P Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
2020
·
Z. Zhou
, S. Lu
, et al.
·
Annals of Oncology
·
2
PDF
P001 Discrepancy of Oncogenic Mutations in Bone Metastasis Derived from Lung Adenocarcinoma
2018
·
L. Huang
, A. Liu
·
Journal of Thoracic Oncology
·
2
PDF
23P SHR-A2009, a HER3-targeted ADC, plus bevacizumab (Bev) for pretreated EGFR-mutated non-squamous (EGFRm nsq) NSCLC: A phase Ib/II study
2026
·
Z. Wang
, Y-L. Wu
, et al.
·
ESMO Open
·
1
PDF
10MO SHR-A2009, a HER3-targeted ADC, plus aumolertinib (A) as 1L or ≥2L treatment for EGFR-mutated (EGFRm) NSCLC: A phase Ib/II study
2026
·
Y-L. Wu
, Z. Wang
, et al.
·
ESMO Open
·
1
PDF
65P SHR-A2009, a HER3-targeted ADC, in advanced solid tumors: Updates from a phase I study
2026
·
Q. Zhou
, Y-L. Wu
, et al.
·
ESMO Open
·
1
PDF
Plasma anti-ATP7A/B autoantibodies as potential biomarkers for the detection and prognosis of non-small cell lung cancer
2025
·
Lulu Zhang
, Aichen Liu
, et al.
·
Clinical Immunology
·
1
60TiP ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC)
2021
·
Y. Cheng
, J. Wang
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
Show more works
View as search
Works count:
48
Citation count:
300
H-index:
8
I10-index:
3
Year
Topic
Type